Ensifentrine: meta-analysis of COVID-19 studies

All studies   Mortality   Recovery   RCTs   RCT mortality   All outcomes  
0 0.5 1 1.5+ All studies -150% 1 45 Improvement, Studies, Patients Relative Risk Mortality -150% 1 45 RCTs -150% 1 45 Late -150% 1 45 Ensifentrine for COVID-19 c19early.org December 2025 Favorsensifentrine Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] death 1/30 0/15 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk All studies -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk 1 ensifentrine COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors ensifentrine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] 1/30 0/15 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk All studies -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk 1 ensifentrine COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Favors ensifentrine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] no recov. 1/30 0/15 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk All studies -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk 1 ensifentrine COVID-19 recovery result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Favors ensifentrine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] death 1/30 0/15 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk All studies -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk 1 ensifentrine COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors ensifentrine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] 1/30 0/15 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk All studies -150% 2.50 [0.11-57.9] 1/30 0/15 150% higher risk 1 ensifentrine COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Favors ensifentrine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] death 1/30 0/15 Improvement, RR [CI] Treatment Control MacDonal.. (DB RCT) -150% 2.50 [0.11-57.9] no recov. 1/30 0/15 Ensifentrine COVID-19 outcomes c19early.org December 2025 Favors ensifentrine Favors control